Manual on meat inspection for developing countries

-



tb tumor in neck :: Article Creator

Tumor Biology Program

Content

The previous Cell Signaling and Metabolism Program was reorganized and renamed as the Tumor Biology Program in 2023. The program consists of 69research members and 15 clinical members representing 16 basic science and clinical departments.

The goal of the program is to better understand the biological mechanisms of cancer development and progression and to use these findings to facilitate enhanced diagnostic and therapeutic approaches. Expertise of program members falls into three broad categories: new discovery (multi-omics), cancer cell biology and the role of the microenvironment, including immune and microbiome alterations. Members focus on multiple different cancer types including pancreas, gastrointestinal, liver, lung, prostate, bladder, brain, and head and neck cancers. Investigators also focus on understanding the signaling and metabolic alterations associated with genetic and molecular changes that drive cancer initiation, progression to metastasis, and acquired therapuetic resistance.

Two Themes with subgroups have evolved based on member expertise, research focus, and collaborative efforts.

  • Cancer Progression Theme
  • Discovery and Modeling
  • Cancer Cell Biology
  • Microenvironment Theme
  • Metabolism and Microbiome
  • Immunology and Stomal Interactions

    • Heading

    Metabolism and Microbiome

    Content

    The Metabolism and Microbiome group focuses on key changes in metabolism in both cancer cells and other cells in the tumor microenvironment. Included are studies focused on the role of the microbiome in cancer development, progression and therapeutic responses.

    Heading

    Immunology and Stromal Interactions

    Content

    The Immunology and Stromal Interactions group focuses on altered immune biology within tumors and how altered pathways affect tumor progression and therapeutic resistance. Included in this group are studies of key stromal cells in the tumor microenvironment and how interactions with cancer cells affect progression and therapeutic resistance.





    Comments

    Post a Comment

    Popular posts from this blog

    Manual on meat inspection for developing countries

    -
    Image
    sinusitis treatment :: Article Creator My 'sinus Infection' Turned Out To Be A One In A Million Nasal Cancer At Just 28 - And Doctors Had To Cut My Eye Out To Save Me By Emily Joshu Health Reporter For Dailymail.Com Published: 06:33 EDT, 20 April 2024Updated: 06:35 EDT, 20 April 2024 A 28 year-old California woman has described the shock of being diagnosed with a deadly sinus cancer that affects fewer than one in a million people - and led to the removal of her right eye. The 'golf ball-sized tumor', which had spread throughout her face, was first mistaken for a sinus infection by the woman's doctors.  Annika, who posts about her condition on TikTok, woke up one morning in 2023 and noticed that the inner corner of her right eye was sore.  While she at first thought nothing of it, by the time the evening rolled around, 'my face started to really, really hurt on the right side,' she said in a video.  The next day, her...
    Read more

    Blogs, Releases Address Impact Of COVID-19 On AIDS, TB, Malaria, Food Security Responses, Other Issues Related To Pandemic - Kaiser Family Foundation

    -
    Image
    Friends of the Global Fight Against AIDS, Tuberculosis and Malaria: The Fatal Consequences of COVID-19 on AIDS, Tuberculosis and Malaria Roopa Darwar, contributor to Friends of the Global Fight (7/27). PAHO: PAHO Director featured in new COVID-19 Exemplars in Global Health program (7/27). UNAIDS: Virtual meeting on the impact of the COVID-19 on HIV programs in the ECOWAS region (7/27). UNICEF: An additional 6.7 million children under 5 could suffer from wasting this year due to COVID-19 (7/27). World Economic Forum: Bill Gates: How HIV/AIDS prepared us to tackle COVID-19 Harry Kretchmer, senior writer with Formative Content (7/27).
    Read more

    Compounds show promise in search for tuberculosis antibiotics - Science Daily

    -
    Compounds tested for their potential as antibiotics have demonstrated promising activity against one of the deadliest infectious diseases -- tuberculosis (TB). Researchers from the John Innes Centre evaluated two compounds with antibacterial properties, which had been produced by the company Redx Pharma as antibiotic candidates, particularly against TB. TB, which is caused by the bacterium Mycobacterium tuberculosis, is often thought of as a disease of the past. But in recent years it has been increasing due, in part, to rising resistance to treatments and decreasing efficacy of vaccines. One strategy in the search for new treatments is to find compounds that exploit well-known existing targets for drugs such as the bacterial enzyme DNA gyrase. This member of the DNA topoisomerase family of enzymes is required for bacterial DNA functionality, so compounds that inhibit its activity are much sought after as antibiotic candidates. Using X-ray crystallography, the team elucidated the ...
    Read more